In Vitro Effects of BCR-ABL Tyrosine Kinase Inhibitors on Endothelial Cells Survival and Functions

Medicine and Dentistry

• In Vitro 100%
• Endothelial Cell 100%
• Cell Survival 100%
• Cell Function 100%
• Tyrosine-Kinase Inhibitor 100%
• Dasatinib 62%
• Ponatinib 62%
• Nilotinib 50%
• Assay 37%
• Cell Adhesion Molecule 37%
• Therapeutic Procedure 25%
• Cells 25%
• Intercellular Adhesion Molecule 1 25%
• Cell Migration 25%
• Lactate Dehydrogenase 25%
• Drug Megadose 25%
• Vascular Cell Adhesion Molecule 1 25%
• Enzyme Linked Immunosorbent Assay 25%
• Bosutinib 25%
• Endothelial Leukocyte Adhesion Molecule 1 25%
• Chronic Myelogenous Leukemia 25%
• Patient 12%
• Monitoring 12%
• Endothelium 12%
• Chemotherapeutic Agent 12%
• Drug 12%
• Inpatient 12%
• Atherosclerosis 12%
• Cell Metabolism 12%
• Necrosis 12%
• Cardiovascular System 12%
• Atherogenesis 12%
• Lipoprotein 12%
• Wound Closure 12%
• Imatinib 12%

Biochemistry, Genetics and Molecular Biology

• Cell Survival 100%
• Cell Function 100%
• Tyrosine Kinase Inhibitor 100%
• Ponatinib 62%
• Dasatinib 62%
• Nilotinib 50%
• Molecule 37%
• Adhesion 37%
• Cell Migration 25%
• Drug Megadose 25%
• Myeloid 25%
• Wound Healing Assay 25%
• Bosutinib 25%
• E-Selectin 25%
• VCAM-1 25%
• ICAM-1 25%
• Development 12%
• Permeability 12%
• Lipoprotein 12%
• Imatinib 12%
• Cell Metabolism 12%
• Tumor Necrosis Factor 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Survival 100%
• Protein Tyrosine Kinase Inhibitor 100%
• Ponatinib 62%
• Dasatinib 62%
• Nilotinib 50%
• Cell Adhesion Molecule 37%
• Lactate Dehydrogenase 25%
• Chronic Myeloid Leukemia 25%
• Bosutinib 25%
• Intercellular Adhesion Molecule 1 25%
• E-Selectin 25%
• Vascular Cell Adhesion Molecule 1 25%
• Enzyme-Linked Immunosorbent Assay 25%
• Drug 12%
• Necrosis 12%
• Atherosclerosis 12%
• Imatinib 12%
• Lipoprotein 12%
• Atherogenesis 12%
• Wound 12%